Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients

• Status: Completed
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: All

Summary

STEMI is a serious type of coronary heart disease, which is a major cause of disability and death. Morphologically the key feature of remodeling is myocyte hypertrophy, myocyte loss from necrosis or apoptosis, as well as interstitial cell growth especially fibroblast proliferation leading to myocardial fibrosis .

Elevated serum LDL-cholesterol concentrations play a proatherogenic role by stimulating inflammation and oxidative processes.

Statins have been documented to retard fibrosis and ventricular hypertrophy by the cessation of myofibroblast activity. Clinical studies have proven that statins not only regulate lipids but also improve myocardial fibrosis, regulate cell proliferation and apoptosis, regulate ventricular remodeling, and protect the myocardium

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damanhour University
• Collaborator: Alexandria University
• Treatments: Atorvastatin; Rosuvastatin Calcium

Criteria

Inclusion Criteria:

1. Electrocardiogram showed abnormal elevation of the ST segment.

2. First myocardial infarction occurred.

3. The patients received one-stage percutaneous coronary intervention (PCI) therapy within 12 h.

Exclusion Criteria:

1. Severe cardiac insufficiency.

2. Hepatic insufficiency (continuous increase of serum transaminase more than 3 times of the upper limit of normal level).

3. Renal insufficiency (creatinine clearance rate <30 mL/min).

4. Addition of others blood lipid lowering and antioxidant drugs during follow up period.

5. Familial hypercholesterolemia.

6. Malignant tumor.

7. Immune system disease.

8. Acute infectious disease.

9. Hypersensitivity to rosuvastatin and Atorvastatin.